Double Blind Study of Trp01 in Patients With Alzheimer's Disease

The clinical trial will be a double-blind, placebo-controlled study with patients being randomized in a 2:1 ratio into groups A and B, respectively: Group A: TRP01 1g b.i.d. for 26 weeks Group B: placebo capsules b.i.d. for 26 weeks After the initial screening, clinic visits will take place at 0, 13 and 26 weeks. The blinding will be maintained until all patients have completed the 26-week trial. Any patients wishing to continue taking the medication upon completion of the trial will be provided a prescription for the drug and may purchase it at their own expense.